KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 120 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $255,000 | +0.4% | 67,929 | +9.6% | 0.01% | -25.0% |
| Q1 2018 | $254,000 | -14.8% | 62,000 | -3.1% | 0.01% | 0.0% |
| Q4 2017 | $298,000 | -34.4% | 64,000 | 0.0% | 0.01% | -52.9% |
| Q3 2017 | $454,000 | -1.9% | 64,000 | 0.0% | 0.02% | -15.0% |
| Q2 2017 | $463,000 | +15.8% | 64,000 | -1.5% | 0.02% | +25.0% |
| Q1 2017 | $400,000 | +6.7% | 65,000 | +1.6% | 0.02% | -11.1% |
| Q4 2016 | $375,000 | +10.3% | 64,000 | 0.0% | 0.02% | -14.3% |
| Q3 2016 | $340,000 | -21.7% | 64,000 | -2.5% | 0.02% | -38.2% |
| Q2 2016 | $434,000 | -16.2% | 65,610 | -40.9% | 0.03% | +47.8% |
| Q1 2016 | $518,000 | -7.7% | 111,000 | 0.0% | 0.02% | -41.0% |
| Q4 2015 | $561,000 | +43.5% | 111,000 | 0.0% | 0.04% | +129.4% |
| Q3 2015 | $391,000 | -21.6% | 111,000 | +122.0% | 0.02% | -15.0% |
| Q2 2015 | $499,000 | +17.4% | 50,000 | +66.7% | 0.02% | +33.3% |
| Q4 2014 | $425,000 | +132.2% | 30,000 | +112.8% | 0.02% | +275.0% |
| Q4 2013 | $183,000 | – | 14,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management I, LLC | 1,312,006 | $16,990,000 | 16.50% |
| VHCP Management, LLC | 1,000,273 | $12,954,000 | 6.97% |
| Cormorant Asset Management, LP | 1,700,000 | $22,015,000 | 6.39% |
| HARVEY CAPITAL MANAGEMENT INC | 890,500 | $11,531,000 | 4.76% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 859,672 | $11,133,000 | 2.50% |
| Rhenman & Partners Asset Management AB | 400,000 | $5,180,000 | 2.03% |
| SECTORAL ASSET MANAGEMENT INC | 2,758,950 | $35,728,000 | 1.54% |
| NORTHPOINTE CAPITAL LLC | 1,289,711 | $16,701,000 | 1.47% |
| Knoll Capital Management, LLC | 200,000 | $2,592,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,483,260 | $19,208,000 | 1.00% |